The REPOSI study by S. Damanti et al.
The REPOSI Study
Sarah Damanti, MD
REPOSI network 
70
internal medicine and 
geriatric wards
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The REPOSI (REgistro POliterapie SIMI) 
study is a collaborative and indipendent
study of the Italian Society of Internal
Medicine (SIMI) and the Mario Negri 
Institute of Pharmacological Research
REPOSI 2010
Nobili A, et al. Pharmacoepidemiol Drg Saf, 2011; 20: 488-96
Steinman MA, et al. JAGS 2006;54:1516-23
Treatment risk paradox
Prevalence of drug use at admission
and at discharge in 1,155 patients
For 148 patients (13.0%), the number of drugs at discharge were fewer than
at admission (delta <0), whereas for 295 (25.4%), there was no difference (delta=0) 
and for 712 (61.6%) there was an increase (delta >0).
Eur J Clin Pharmacol (2011) 67:507–519
Adverse events %
Urinary tract infections 11,2
Pneumonia 7,8
Anemia 5,3
Cardiac arrythmias 5,3
Fluid/electrolyte disorders 3,6
Intestinal infections 3,4
Fever 3,2
Heart failure 2,9
Acute respiratory failure 2,4
Acute confusional state 2,2
Sepsis 2,2
66 Italian internal and geriatric 
medicine hospital wards, enrolled 
1,267 in-patients 
412 patients (32.5%) experienced 
at least one AE and 19 of them  
died as a consequence of an AE
Independent predictors of AEs 
✓ previous admissions to 
hospital in the past 3 months 
✓ bladder catheter 
✓ proton-pump inhibitor  
✓ immunosuppressant therapy 
Clinical adverse events during hospital stay
